Changes in Electroretinogram and Contrast Sensitivity After PASCAL Treatment (NCT00563043) | Clinical Trial Compass
TerminatedPhase 4
Changes in Electroretinogram and Contrast Sensitivity After PASCAL Treatment
Stopped: Undefined
Mexico8 participantsStarted 2007-10
Plain-language summary
Laser photocoagulation has become the treatment of choice in PDR. Laser photocoagulation has become the treatment of choice in PDR. The aim is to destroy a substantial portion of the peripheral retina in order to reduce the angiogenic stimulus (decrease the difference between oxygen demand and the administration). Their effectiveness is determined by the extent of destruction of the retina (2.4).
Who can participate
Age range
25 Years – 95 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Patients older than 25 years, with a diagnosis of severe NPDR or PRD.
* Good pupil mydriasis (minimum 5mm) With clear media
* Patients without previous laser treatment or treatment with antiangiogenic drug.
Exclusion Criteria:
* Patients who do not accept informed consent.
* Patients with clinical macular Edema before treatment.
* Significant corneal opacity.
* Patients with other eye diseases that interfere with the studies required for the monitoring of patients.
* History of refractive surgery, glaucoma or ocular hypertension, intraocular inflammation, choroiditis multifocal, retinal detachment, optic neuropathy (4).
* Patients with tractional retinal detachment due to abundant fibrovascular
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Changes in a wave amplitude
Timeframe: 12 weeks
2
changes in b wave amplitude
Timeframe: 12 weeks
3
changes in ERG implicit time
Timeframe: 12 weeks
Trial details
NCT IDNCT00563043
SponsorAsociación para Evitar la Ceguera en México